Neurology

Research shows about one in four adults become delirious during a hospital admission. That’s about 500,000 Canadians a year. Age is a risk factor, as delirium presents in about half of hospitalized patients ages 65 and older.

That information could be reassuring or terrifying, but for now it’s a potential tool to speed drug development by helping to identify and enroll high-risk people into studies of possible Alzheimer’s treatments or preventive strategies.

Recent research shows tiny particles from wildfire smoke—known as PM2.5, fine particulate matter—are so small they can travel deep into the lungs. But they don’t always end their journey there.

The antibody targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.

Tau is one part of a toxic duo fueling Alzheimer’s but prior attempts to develop drugs that can target the protein have failed.

CMAJ authors provide decision-making pathway to help clinicians weigh benefits and risks and engage with patients and caregivers.

Get the info you need on this new product, part of our drug news roundup for July.

Large scale study evaluates the association between glucagon-like peptide-1 (GLP-1) receptor agonist use and smell and taste disturbances.